Scientists offer hope for genetically determined obesity
London, June 3: Unable to maintain weight loss due to your genetic predisposition to obesity? Take heart, an injectable drug widely used to lower blood sugar levels can help you fight overweight, suggest a study.
Around two to six per cent of all people with obesity develop obesity already in early childhood because they are genetically programmed to do so.
Obesity-causal mutations in one of their "appetite genes" gives them a strong genetic predisposition for developing obesity, also called monogenic obesity. Their experience of hunger is over-ruling and their feeling of satiety limited.
Researchers discovered that this group of people with obesity can lose weight with the help of the medicine liraglutide -- a modified form of the appetite-inhibiting hormone GLP-1 naturally secreted from the intestine when we eat.
"The appetite-inhibiting drug liraglutide has a positive effect on them. They feel less hungry and lose six per cent of their body weight within four months," said lead author Signe Sorensen Torekov, associate professor at the University of Copenhagen in Denmark.
In the study, published in the journal Cell Metabolism, the team have examined a small group with obesity caused by pathogenic mutations in the so-called MC4R gene and those with obesity without the mutations.
Both groups were treated with the medicine for four months; no changes were made to their diet and level of exercise in this period.
The individuals with this most common form of monogenic obesity lost 7 kg of their body weight compared to 6 kg for the people with common obesity.
Medicine acting as an analogue to our natural GLP-1 hormone is already available, as it has been approved by both the US Food Drug Association and European Medicines Agency for the treatment of obesity and Type 2 diabetes.
The study thus makes it possible to treat the most common form of genetically caused obesity, where patients respond poorly to existing treatments, the researchers noted.
As MC4R mutations cause obesity already in early childhood, the researchers hope the results can pave the way for new studies on young people in the future.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
RSS man's defamation case against Rahul: Key witness unavailable, hearing adjourned to Dec 20
Thane (PTI): A court in Bhiwandi in Thane district on Saturday adjourned the hearing in the criminal defamation case filed against Congress leader Rahul Gandhi by a Rashtriya Swayamsevak Sangh (RSS) worker to December 20 due to non-availability of a crucial prosecution witness.
Advocate Narayan Iyer, counsel for Rahul Gandhi, confirmed the adjournment, stating that the witness, Ashok Saykar, currently Deputy Superintendent of Police in Barshi in Solapur, could not remain present due to personal reasons.
Saykar's evidence is now likely to be recorded on December 29.
His testimony is considered key because he, as police sub inspector in 2014, conducted the preliminary inquiry into the private defamation matter under Section 202 of the Code of Criminal Procedure (CrPC).
It was on the basis of Saykar's submitted report that the court subsequently issued process (summons) against Rahul Gandhi under Section 500 of the Indian Penal Code (IPC).
The criminal defamation case was filed by local RSS worker Rajesh Kunte following a speech given by Rahul Gandhi at an election rally near Bhiwandi on March 6, 2014.
The case stems from the Congress leader's alleged statement that "the RSS people killed (Mahatma) Gandhi."
The matter is being heard by Bhiwandi Joint Civil Judge, Junior Division, P M Kolse.
The hearing had previously been adjourned on November 15 after the complainant's counsel, Advocate Prabodh Jaywant, moved an application seeking permission to examine Saykar, who had submitted the probe report to the court.
The matter was originally scheduled for November 29 but was deferred to December 6 after Rahul Gandhi's legal team sought an adjournment citing their non-availability. The proceedings will now resume on December 20.
